Status:
UNKNOWN
Potentiation of Chemotherapy in Brain Tumors by Zinc
Lead Sponsor:
Sheba Medical Center
Conditions:
Newly Diagnosed Glioblastoma Who Underwent at Least Partial Resection of the Tumor Surgically
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Glioblastoma (GB) is the most common and aggressive type of primary malignant brain tumor in adults. Despite advances in surgical resection, radiotherapy and chemotherapy, prognosis remains very poor....
Detailed Description
We propose a single arm phase II clinical trial in 30 newly diagnosed GBM patients who will be treated with the standard chemo-radiotherapy with the addition of daily zinc. We will follow the toxicity...
Eligibility Criteria
Inclusion
- Males and Females,
- age ≥ 18 years old,
- newly diagnosed GBM, Karnofsky performance status of ≥ 70,
- after partial resection or gross tumor resection (GTR) who recovered from surgical resection.
Exclusion
- GB patients with less than 20% of tumor removed,
- Prior treatment for GB (other than surgical resection),
- any known malignancy outside of the brain in the last 5 years,
- in ability to swallow drugs.
Key Trial Info
Start Date :
July 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04488783
Start Date
July 30 2020
End Date
December 30 2022
Last Update
July 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Israel